GlassScriptPhysician profile
Alex Breslau
NPI 1891287280
$449.17
in general payments reported to CMS, 2019-2025
10 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $204 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.18 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $93.74 | 2025 | Uptravi, Opsumit, Opsynvi |
| Exact Sciences Corporation | $75.72 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $74.20 | 2024-2025 | |
| Madrigal Pharmaceuticals | $46.96 | 2024 | Resmetirom |
| Pfizer INC. | $44.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $38.74 | 2024-2025 | |
| Viiv Healthcare Company | $25.00 | 2025 | Rukobia |
| Astrazeneca Pharmaceuticals LP | $22.17 | 2024 | Fasenra |
| Glaxosmithkline, LLC. | $14.02 | 2025 | Shingrix |
| Mallinckrodt Hospital Products INC. | $13.72 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Breslau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.